Growth in the Dupixent market is shaped as much by regulatory momentum as by disease prevalence. Polaris Market Research values the market at USD 15.29 billion in 2025, with a 2026 estimate of USD 16.36 billion and a projection of USD 28.95 billion by 2034 at a CAGR of 7.35%. The report highlights the continuous broadening of approved indications and age groups, which enlarges the potential patient base with every new approval.

Approvals Are Widening the Patient Base

The U.S. FDA approved Dupixent for adults with bullous pemphigoid on June 20, 2025, making it the only targeted medicine for this condition. Earlier, in February 2025, the FDA had accepted the supplemental application under priority review. In chronic spontaneous urticaria, the FDA approved the therapy for patients aged 12 years and above on April 18, 2025, while Japan was the first country to approve it for this group, on February 16, 2024.

In April 2026, the FDA extended approval to children aged two to 11 years who remain symptomatic despite H1 antihistamine treatment, and the European Commission approved use in the same age group that month.

COPD and the Pipeline

The chronic obstructive pulmonary disease segment is anticipated to register the highest growth rate by indication during the forecast period. On July 3, 2024, the European Commission approved Dupixent as an add-on maintenance treatment for adults with uncontrolled disease characterized by raised blood eosinophils. Polaris notes that Phase 3 trials showed promising results in reducing exacerbations in a subset of patients, potentially unlocking a large and previously untapped market.

The pipeline extends further, with studies in chronic prurigo nodularis, lichen simplex chronicus and allergic fungal rhinosinusitis, while Sanofi and Regeneron explore rare diseases such as eosinophilic gastritis and food allergies.

Pediatric studies also aim to extend use to younger populations, which could further strengthen its presence in chronic disease management.

Retail Channels and Home-Based Management

The retail pharmacies segment is expected to expand as patients move from initial hospital-based care to managing their conditions at home. Polaris links this shift to growing familiarity with long-term use and self-administration, as well as specialty pharmacy services within retail chains that provide proper handling, patient education and adherence programs.

Entry Barriers and Competitive Position

Entry barriers across biologic therapy are high. Research and development spending on monoclonal antibodies often exceeds USD 1–2 billion, and production requires cGMP-compliant facilities and stringent cold-chain logistics. With patent protection secured until 2033 in key areas such as the U.S. and Japan, the threat from biosimilars is described as low.

Substitution risk is also low. Tralokinumab and lebrikizumab target only IL-13 and show narrower efficacy, while most bispecific antibodies remain in early-phase development. Sanofi and Regeneron lead through a strategic partnership that drives clinical development and global expansion.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/dupixent-market 

Regulation, Cost and Future Outlook

Regulation shapes the trajectory. FDA and EMA approvals rely on robust clinical datasets, orphan drug designations in rare diseases offer exclusivity extensions and tax credits, and strict health technology assessments in Europe require demonstrated cost-effectiveness for favorable pricing and reimbursement.

Looking ahead, Polaris expects steady growth as demand rises for biologics that specifically target inflammatory and immunological conditions. Increased disease prevalence, indication expansion, wider access to specialty care and greater patient awareness are the main drivers, while innovation in biologic drugs and personalized medicine is expected to shape the landscape. Real-world data collection and health economic studies also continue to reinforce the value proposition, supporting reimbursement and formulary access through 2033.

Key Players

• Regeneron Pharmaceuticals
• Sanofi

Conclusion

The Dupixent market is being driven by a steady flow of approvals, a promising pipeline and strong structural barriers that protect its position. Valued at USD 15.29 billion in 2025 and projected to reach USD 28.95 billion by 2034, it offers a clear example of how label expansion sustains long-term demand. Decision-makers should follow upcoming regulatory decisions and channel shifts, as both will influence how widely the therapy reaches patients.

More Trending Latest Reports By Polaris Market Research:

Oat Milk Market

Airlines Market

Salmon Fish Market

5G IoT Market

3D Digital Asset Market

Workplace Stress Management Market

Workplace Stress Management Market

Salmon Fish Market

Methanol Ships Market